HealthQuill Drugs
Intensive diet and lifestyle changes may forestall a cognitive decline in Alzheimer’s disease and make progress for patients during early stages, a study finds.
Drugs Health Medical

New study identifies possible cause of Lupus, may help in developing cure

HQ Team July 16, 2024: A new study by Northwestern Medicine and Brigham and Women’s Hospital researchers has identified a possible cause for.

Read More
Novo Nordisk, has been denied approval for its type 1 diabetic medicine by the USFDA, according to the Danish drugmaker.
Drugs Health Pharma

FDA declines approval for Novo Nordisk’s diabetic medicine

Novo Nordisk, has been denied approval for its type 1 diabetic medicine by the USFDA, according to the Danish drugmaker.

Read More
OraSure Technologies’ hepatitis C virus self-test has been prequalified by the World Health Organization in a global bid to eliminate the disease.
Drugs Health Pharma

Global health body prequalifies OraQuick’s hepatitis C virus self-test

OraSure Technologies’ hepatitis C virus self-test has been prequalified by the World Health Organization in a global bid to eliminate the disease.

Read More
Pharmacy benefit managers, who handle about 95% of US prescriptions, are inflating drug costs and squeezing independent pharmacies, according to a report.
Drugs Health Pharma

Pharmacy benefit managers in the US wielding ‘enormous power’: FTC report

Pharmacy benefit managers, who handle about 95% of US prescriptions, are inflating drug costs and squeezing independent pharmacies, according to a report.

Read More
Intensive diet and lifestyle changes may forestall a cognitive decline in Alzheimer’s disease and make progress for patients during early stages, a study finds.
Drugs Health Pharma

Diet, exercise, socialisation may help in early stage Alzheimer’s disease

Intensive diet and lifestyle changes may forestall a cognitive decline in Alzheimer’s disease and make progress for patients during early stages, a study.

Read More
Antitrust regulators in the UK have cleared a $3.1 billion acquisition of Olink Holding AB by Thermo Fisher Scientific Inc., following an initial probe that began in May last year.
Drugs Medical Pharma

Thermo Fisher’s $3.1 billion buy of Olink gets UK competition regulators’ nod

Antitrust regulators in the UK have cleared a $3.1 billion acquisition of Olink Holding AB by Thermo Fisher Scientific Inc., following an initial.

Read More
Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor to treat inflammatory bowel disease.
Drugs Health Pharma

Eli Lilly to buy Morphic for $3.2 b in cash to expand integrin therapies

Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor.

Read More
Urgent steps are also needed to study the dynamics of the circulating viral strains about its vector, hosts and environment for developing effective preventive and control strategies. Research into the genetic structure of the WNV could also help in future vaccine development strategies. 
Drugs Health Opinion Pharma

Opinion: West Nile Virus’ genetic sequence needs in-depth study

Urgent steps are needed to study the dynamics of the circulating viral strains about its vector, hosts and environment for developing effective preventive.

Read More
The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed an extended nine months of survival.
Drugs Health Pharma

AstraZeneca’s medicine for non-small lung cancer gets EU nod

HQ Team July 5, 2024: The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed.

Read More
Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment of Merck & Co.
Drugs Health Pharma

Roche ends small cell lung cancer trials as results show ‘reduced efficacy’

Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment.

Read More